TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevention of side effects of hypoxia
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Choice Reaction Time (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of Metoject® prefilled pen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of deep vein thrombosis by portable ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diagnosis of deep vein thrombosis by doppler ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: angiographic in-segment late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous Tear Evaporation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum VEGF-C Level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of subjects achieving LDL-C goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Scores With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPAR (Biopsy Proven Acute Rejection)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Trough FEV1 at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Small Artery Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Large Artery Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCt (Area Under Curve last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total nasal symptom score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-τ of phentermine, topiramate, sitagliptin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of phentermine, topiramate, sitagliptin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient recovery from visceral leishmaniasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural Alcohol Cue Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CgA levels at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to the intervention
Endpoint domain: Mortality/survival
Primary endpoint: Rate of maxillary canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-Observer Repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pediatric cancer patients undergoing testicular tissue cryopreservation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neutralizing antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in worst NRS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average NRS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet quality as measured by NuVal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Perioperative Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: myelotoxicity of fractionated dose of 177Lu-J591
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: preliminary efficacy (response rate) of 177Lu-J591
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of bacterial pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time from diagnosis to brace fitting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients requesting additional support
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Are appropriate braces fitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Fluorescence Index (MFI) of Donor Specific Alloantibodies (DSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events leading to withdrawal from the study
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary functioning (FEV-1, FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hospital and emergency department utilization (for asthma exacerbation)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence, intensity and causal relationship of any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of sinusoidal obstruction syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Swallow Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiorespiratory manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intima media thickness of carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inhibition of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of any postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: HDL Subfractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Adverse Events that meets the DLT definition
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Adverse Events grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-normalized tacrolimus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Substrate utilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skindex quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Language Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in serum and urine proteomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic and biochemical markers of early disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression and temporal alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage Change in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wound odour assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with other serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean shade change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful bilateral placement of the ESS310 insert at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of treatment-associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Theory of Mind Battery & Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in QbInattention score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal subcutaneous and visceral fats volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caregiver Quality of Life Index - Cancer
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of an Adjudicated Secondary Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Liver Iron Content (LIC) Change-from-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival (assessed until death)
Endpoint domain: Mortality/survival
Primary endpoint: QOL (evaluated after courses 3 & 5 then every other course)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % of subjects with >/= grade 3 hematopoietic & non-hematopoietic toxicities (assessed 3/week on treatment & continuing until counts recover)
Endpoint domain: Adverse events/effects
Primary endpoint: Counts of mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of composite z ecological score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mean monthly headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between POC INR and laboratory INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Extravascular Lung Water (EVLW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glucose incremental Area Under the Curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants who will die during the follow up period
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of ultrasound-guided axillary lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in ASIA motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in ASIA sensory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Days of care outside the home
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma selenoprotein P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic Survival
Endpoint domain: Mortality/survival
Primary endpoint: Prosthetic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Primary Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant crying and fussing behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rise in Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of subjects that display biomarkers of OCD-related distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects that display biomarkers of DBS-induced hypomania
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mMASI (Modified Melasma Area and Severity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Contrast enhancement effect on tumor-like lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bioequivalence of generic GPO ritonavir with Norvir®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Clearance of Actinic Keratosis (AK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of confirmed hepatitis E cases
Endpoint domain: Adverse events/effects
Primary endpoint: Energy target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in total size of lesion and total size of CNV at 12, 24 and 54 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in uGAG Chondroitin Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any ≥ 50% Decrease in uGAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily assessment of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glucocerebrosidase levels in blood and cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ambroxol levels in blood and cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vaginal microbiome distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brainstem dysfunction prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin or tendon location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Treatment-related Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Predictive Value of Polymerase Chain Reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of grade 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of exercise intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of exercise intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-tlast))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of lovastatin and lovastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Discussions About End of Life Care Goals/Wishes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of diversity of intestinal flora in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of diversity of urethral flora in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of abundance of intestinal flora in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of abundance of urethral flora in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of concentration of purine metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of submucosal cement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of HTPPE
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Pain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 minutes walking test (6-MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of adequate response
Endpoint domain: Mortality/survival
Primary endpoint: 1-year Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hallucination Change Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in CAPS-5 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of chemotherapy and IL-2 administration
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Simple Reaction Time (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Crohn's Disease (CD) or ulcerative colitis (UC) who visit the participating sites
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with different degrees of CD and UC severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use rates of classes of drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Non-transferrin-bound Iron Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients alive and progression-free at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Tensile strength of 4-0 nylon sutures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: level of serum p-cresyl sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VRS Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Duration of saddle block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Supernatant Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ART initiation retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Postoperative Hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to recruit patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant willingness to be randomized and acceptability of the usual care condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with and acceptability of the behavioral techniques
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence differences
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AUClast of Pregabalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Pregabalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Pregabalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Pregabalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Efficacy for Managing Chronic Disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects Not Able to Tolerate Ambrisentan
Endpoint domain: Adverse events/effects
Primary endpoint: PK-Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK-Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes